Pharmaceuticals

XUANZHUBIO-B

Xuanzhu Biopharma Sees Over 70% Revenue Growth in 2025 With Commercialization Breakthrough Imminent

Xuanzhu Biological Announces Preliminary Clinical Trial Results for NG-350A

Xuanzhu BioPharma Announces Superior Results for Difluorzan in Phase III Clinical Trial Compared to Crizotinib

Xuanzhu Biopharma's Anellazole Sodium Enteric-Coated Tablets Approved for Phase III Clinical Study

Xuanzhu Bio-B Enters into License and Supply Agreement for Pyloricyclin and Delaroqu

XUANZHUBIO-B released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 18.52 M, actual EPS HKD -0.1535

XUANZHUBIO-B released FY2025 Q4 earnings on March 30, 2026 (BJT), with actual revenue of HKD 18.84 M and EPS of HKD -0.1572

XUANZHUBIO-B released FY2025 Annual Earnings on March 30 (BJT), actual revenue HKD 56.58 M, actual EPS HKD -0.5772

XUANZHUBIO-B released FY2025 9 Months Earnings on March 30, 2026 (BJT), with actual revenue of HKD 37.89 M and EPS of HKD -0.42

Xuanzhu Bio-B Reports 72% Revenue Growth in 2025 Annual Results

Xuanzhu Bio-B Announces Positive Results of Pyrlosil III Phase Clinical Trial

Xuanzhu Biopharma Completes Patient Recruitment for Phase III Esophagitis Drug Trial

XUANZHUBIO-B to Release FY2025 Earnings on March 30, 2026 (BJT)

Xuanzhu Pharmaceutical to Hold Board Meeting to Discuss 2025 Earnings and Dividend Policy

SinoUnion Pharmaceutical's Innovative Drug Pyrolisib Approved for New Indication

Xuanzhu Bio-B's Anelarazole Sodium Enteral Tablet Renewed for Inclusion in the 2025 National Basic Medical Insurance Drug List

Xuanzhu Biotech's Innovative Drug First Included in the 2025 National Medical Insurance Directory

Xuanzhu Biopharma's Introduced NG-350A Receives FDA Fast Track Designation

Xuanzhu Bio-B Displays Mid-Stage Results of Pyrolisib Combined Treatment for Breast Cancer in Phase III Clinical Trial

Multiple Biotech Companies Complete Financing and Technology Licensing, Innovative Pharma Debuts on Hong Kong Exchange

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02565

02659

02575

01796

In the past hour, the Hong Kong stock market has shown a clear divergence, with the strong performance of the pharmaceutical sector attracting a significant inflow of funds, particularly in stocks like PEGBIO CO-B and BAO PHARMA-B, which have seen notable gains, indicating an increase in short-term enthusiasm. Meanwhile, technology stocks appear relatively weak, with the declines of METASPACEX and Yimu Group drawing market attention, suggesting a rapid switch of funds between different sectors. Overall volatility is high, and the sentiment of short-term traders is fluctuating, with a faster market rhythm. The stock with the largest movement in the past hour, PEGBIO CO-B, has surged by 23.15%, rapidly attracting funds under the influence of the pharmaceutical sector, leading to heightened short-term sentiment and drawing the attention of many investors. The strong performance of this stock seems to inject vitality into the entire sector, driving up other related stocks. Strong stocks include: 1. BAO PHARMA-B: up 18.49%, with continuous inflow of funds against the backdrop of increased market enthusiasm, showing impressive short-term performance. 2. XUANZHUBIO-B: up 16.00%, recent strong trends reflect market confidence in its future development. 3. Jingjiu Kangliao: up 15.87%, gaining favor from investors as the pharmaceutical sector becomes active. 4. Zhongke Group Holdings - New: up 15.38%, with significant short-term fund support amid high market sentiment. 5. Silu Di Pharmaceutical Co., Ltd.: up 15.12%, with the stock's rise reflecting optimistic expectations for the pharmaceutical industry

HK Stock Alerts

PEGBIO CO-B

BAO PHARMA-B

METASPACEX

THAC GROUP

3D MEDICINES

CHINA STAR ENT

Hong Kong Stock Movement Update: Biopharmaceutical stocks rebound strongly, PEGBIO CO-B rises 23%, METASPACEX falls 15%

XUANZHUBIO-B rose 16.00%; CSPC Pharmaceutical Group fell 2.57%, with a transaction volume of HKD 422 million; China Biologic Products fell 1.67%, with a transaction volume of HKD 222 million; Hansoh Pharmaceutical fell 2.90%, with a transaction volume of HKD 180 million; Heng Rui Medicine fell 4.18%, with a market value of HKD 417.8 billion

CSPC PHARMA

SBP GROUP

HANSOH PHARMA

HENGRUI PHARMA

Hong Kong Stock Movement: XUANZHUBIO-B Rises 16%! Clear Capital Flow, Market Sentiment Triggers Volatility Attention

02661

00326

01626

02255

09936

00290

09887

02632

QINGSONG HEALTH(02661) fell 24.2%, with a trading turnover 244.8 Million HKD, and a year-to-date fell 57.2%. CHINA STAR ENT(00326) fell 20.14%, with a trading turnover 119.0 Million HKD, and a year-to-date rose 123.4%. PEGBIO CO-B(02565) fell 19.15%, with a trading turnover 53.6 Million HKD, and a year-to-date fell 71.7%.

Top Gainers&Losers

QINGSONG HEALTH

JIA YAO HLDGS

HAICHANG HLDG

XIMEI RESOURCES

GOFINTECH QUANT

LEADS BIOLABS-B

NEW VISION CO

Top 10 HK Stock Losers (5.13)

00460

Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, has completed the full circulation of its H shares, converting over 357 million previously unlisted shares. This brings Xuanzhu's total issued share capital to nearly 518 million H shares on the Hong Kong Stock Exchange. The move enhances liquidity and market access, supporting Sihuan's strategy in the biopharmaceutical sector. Sihuan, founded in 2001 and listed since 2010, focuses on innovative drugs and aims to lead in medical aesthetics and biopharma in China.

Tip Ranks

SIHUAN PHARM

Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

02656

02635

01333

01277

02685

03881

09993

06651

QINGSONG HEALTH(02661) fell 31.33%, with a trading turnover 116.0 Million HKD, and a year-to-date fell 42.2%. 160 HEALTH(02656) fell 17.82%, with a trading turnover 223.0 Million HKD, and a year-to-date fell 71.9%. NUOBIKAN(02635) fell 16.81%, with a trading turnover 145.9 Million HKD, and a year-to-date fell 46.5%.

160 HEALTH

NUOBIKAN

BRETON

KINETIC DEV

QUANTGROUP

CIDI

RADIANCE HLDGS

51WORLD

Top 10 HK Stock Losers (5.6)

XUANZHUBIO-B rose 17.90%; Heng Rui Medicine rose 4.94%, with a transaction amount reaching HKD 240 million; Stone Pharmaceutical Group rose 0.11%, with a transaction amount reaching HKD 161 million; Hansoh Pharmaceutical rose 0.45%, with a transaction amount reaching HKD 122 million; China Biologic Products fell 1.20%, with a market value of HKD 108 billion

Hong Kong Stock Movement: XUANZHUBIO-B rises 17.90%, clinical research shows significant efficacy boosting market confidence

00179

02655

03277

06682

00551

01773

JOHNSON ELEC H(00179) fell 17.06%, with a trading turnover 464.6 Million HKD, and a year-to-date fell 28.3%. QINGSONG HEALTH(02661) fell 16.6%, with a trading turnover 101.5 Million HKD, and a year-to-date fell 26.7%. GUOXIA TECH(02655) fell 16.11%, with a trading turnover 395.3 Million HKD, and a year-to-date fell 20.9%.

JOHNSON ELEC H

GUOXIA TECH

GPIXEL

PHANCY

YUE YUEN IND

TIANLI INT HLDG

Top 10 HK Stock Losers (4.22)

02650

06808

01872

06166

02198

02096

QINGSONG HEALTH(02661) fell 60.34%, with a trading turnover 260.9 Million HKD, and a year-to-date fell 11.9%. GUOXIA TECH(02655) fell 12.46%, with a trading turnover 738.2 Million HKD, and a year-to-date fell 4.4%. ZHIDA TECH(02650) fell 11.7%, with a trading turnover 51.4 Million HKD, and a year-to-date fell 1%.

ZHIDA TECH

SUNART RETAIL

GUAN CHAO HLDGS

CHINA SANJIANG

SIMCERE PHARMA

Top 10 HK Stock Losers (4.20)

Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, announced promising Phase III trial results for its ALK inhibitor dirozalkib in treating ALK-positive advanced non-small cell lung cancer. The trial demonstrated that dirozalkib significantly improved median progression-free survival compared to crizotinib, along with better response rates and safety profiles. This strengthens Xuanzhu's oncology portfolio and supports Sihuan's innovative drug strategy. The company is focused on developing first-in-class medicines and has a market cap of HK$13.53B, with a year-to-date price performance of 17.89%.

First Trust NYSE Arca Biotech Index Fd

Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib

XUANZHUBIO-B(02575.HK)